Last reviewed · How we verify
Emervel® Touch
Emervel® Touch is a hyaluronic acid-based dermal filler that restores volume and smooths wrinkles by integrating into the dermis.
Emervel® Touch is a hyaluronic acid-based dermal filler that restores volume and smooths wrinkles by integrating into the dermis. Used for Correction of facial wrinkles and folds, Facial volume restoration.
At a glance
| Generic name | Emervel® Touch |
|---|---|
| Sponsor | Hexsel Dermatology Clinic |
| Drug class | Dermal filler |
| Target | Hyaluronic acid receptor (CD44) |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Aesthetics |
| Phase | FDA-approved |
Mechanism of action
Emervel® Touch contains stabilized hyaluronic acid (HA) that binds water and provides structural support to the skin, filling in facial lines and wrinkles. The product is designed for superficial to mid-dermal injection, providing natural-looking results with gradual integration into surrounding tissue. It is typically used for aesthetic correction of facial wrinkles and volume loss.
Approved indications
- Correction of facial wrinkles and folds
- Facial volume restoration
Common side effects
- Injection site erythema
- Injection site swelling
- Injection site bruising
- Tenderness at injection site
- Temporary nodules
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Emervel® Touch CI brief — competitive landscape report
- Emervel® Touch updates RSS · CI watch RSS
- Hexsel Dermatology Clinic portfolio CI